Business
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language
Elanco Animal Health Incorporated (NYSE: ELAN) today announced important updates to the U.S. Zenrelia label, following the Food and Drug Administration (FDA) review of supplemental scientific data.
About this update from Elanco Animal Health Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"FDA now concludes "t he totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling"i","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Further evaluation of supplemental scientific data drove this FDA update; data now peer-reviewed and published","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-world success and experiences from dermatologists and general practice veterinarians around the U.S. and the world further demonstrate Zenrelia's efficacy","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":444,"olType":false},{"type":"text","content":"INDIANAPOLIS, Sept. 23, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced important updates to the U.S. Zenrelia label, following the Food and Drug Administration (FDA) review of supplemental scientific data.","length":242,"tagName":"p"},{"type":"image","alt":"Elanco logo (PRNewsfoto/Elanco Animal Health)","displaySize":"","headline":null,"caption":"Elanco logo (PRNewsfoto/Elanco Animal Health)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/3e0d7ba65d33b7150e97f71c77abc8af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM_acgCT_vHsVMsjwpFxgA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3e0d7ba65d33b7150e97f71c77abc8af","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2309278/Elanco_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Approved by the FDA in September 2024, Zenrelia is an effective, convenient, and safe once-daily oral JAK inhibitor for control of itching and inflammation associated with skin allergies in dogs at least 12 months of age. Over half a million dogs around the world have been treated with Zenrelia. Elanco is inspired by the positive and growing feedback from dermatologists, general practice veterinarians and pet owners.","length":420,"tagName":"p"},{"type":"text","content":"At launch, the U.S. Zenrelia label included language based on the outcome of a laboratory study of unvaccinated dogs dosed at three times the label dose of Zenrelia. During that study, an outbreak of...